MedTrace Logo

Cannabinoid Modulation of Pain

NCT01595620 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-03-09

No results posted yet for this study

Summary

The purpose of this study is to test the effects of cannabinoids on pain response using a variety of human experimental pain models.

Conditions

Interventions

OTHER

Thermal

Thermal sensation/pain testing

OTHER

Electrical

Electrical sensation/pain testing

OTHER

Capsaicin

Intradermal Capsaicin

DRUG

THC

Active THC (0.01 mg/kg) administered over 10 minutes

DRUG

THC

Active THC (0.03 mg/kg) administered over 10 minutes

DRUG

Placebo

Control: small amount of alcohol with no THC, administered over 10 minutes

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Deepak C D'Souza, M.D. · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-09
Primary Completion
2012-04-19
Completion
2012-04-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01595620 on ClinicalTrials.gov